Latest Commercialisation News

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Eden Innovations has unveiled EdenShield®, a new division focused on commercialising advanced carbon nanotube-enhanced materials and dual-fuel systems for defence and critical infrastructure, aiming to tap into a rapidly expanding global aerospace and defence market.

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.

Axel REE is accelerating its in situ recovery (ISR) mining trials at the Caladão Project in Brazil, targeting rare earth elements and gallium extraction through a low-cost, environmentally friendly method. The company is fully funded for pilot wellfield trials at the Woolrich deposit, with expansion potential at Paraíso and Tiger Creek.

Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.

Tivan Limited has confirmed its Speewah Fluorite Project can produce premium acidgrade fluorspar suitable for hydrofluoric acid, backed by positive technical assessments from Asian end-users. The company is advancing pilot production and finalising offtake agreements with Sumitomo Corporation and JOGMEC.

ION Video Ltd has responded to ASX inquiries by confirming its recent discussions with Meta Platforms and Alphabet remain preliminary, with no binding agreements or commercial terms agreed. The company emphasised that the engagements are exploratory and non-binding, explaining why earlier disclosure was not required.

Neurizon Therapeutics has secured an additional A$2.7 million through a placement addressing the shortfall from its entitlement offer, lifting total proceeds to approximately A$8.5 million. This fresh capital strengthens the biotech’s balance sheet and provides financial flexibility as it advances its lead ALS drug NUZ-001 through pivotal clinical stages.

BlinkLab has secured A$17.5 million through an oversubscribed placement to fuel regulatory trials and commercial launch of its AI-driven autism and ADHD diagnostic tools.

Iondrive Limited has confirmed over 90% extraction of key rare earth elements neodymium and praseodymium from US commercial samples, exceeding prior economic assumptions and advancing its modular recycling technology toward commercial deployment.

GoldArc Resources has locked in a binding agreement with Mineral Mining Services to fully fund the development of its Leonora South gold deposits, removing capital barriers and setting a clear path to production.

Temas Resources is tapping the Canadian market with a $1.5 million flow-through share placement aimed at advancing its titanium projects in Quebec. The raise supports exploration expenses tied to its proprietary processing technology and resource development.